Mr. Brian McClelland reports

APOTEX RECEIVES INVESTMENT GRADE ISSUER RATING FROM MORNINGSTAR DBRS AND ANNOUNCES AMENDED & RESTATED CREDIT AGREEMENT

Apotex Health Corp. has successfully completed an amended and restated credit agreement, establishing a financing framework aligned with the company's evolution as a publicly traded, investment-grade-rated issuer.

The amended credit agreement reflects Apotex's receipt of an inaugural BBB (low) investment-grade rating from Morningstar DBRS, and includes updated pricing and fees. The amended credit agreement terms provide Apotex with lower borrowing costs, reflecting its investment-grade credit rating, as well as covenants that allow for greater operational flexibility. The amended credit agreement provides term loan facilities, as well as a revolving credit facility with capacity of $1.2-billion. The credit facility is provided by a syndicate of lenders, led by Bank of Nova Scotia as the administrative agent, and Scotiabank, RBC Capital Markets and TD Securities, as joint lead arrangers and joint bookrunners.

"This amendment to our credit facility represents an important milestone in our continued progression as a public company," said Brian McClelland, chief financial officer, Apotex. "Achieving investment-grade financing terms reflects the strength of our business, balance sheet and cash flow profile. The amended credit agreement lowers our cost of capital, enhances financial flexibility and supports our long-term growth strategy."

Apotex expects the new financing framework to support continuing investment, operational execution and long-term shareholder value creation.

About Apotex Health Corp.

Apotex is a Canadian-based global health company. The company improves everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, Apotex is the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

We seek Safe Harbor.